# Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

> **NCT00151333** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 16 (—)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** SRA-333

## Key facts

- **NCT ID:** NCT00151333
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 16 (—)
- **Last updated:** 2009-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151333, "Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00151333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*